Immunomodulator UDIZ-002

Within our portfolio, we have the UDIZ-002 project, whose objective is the development of a ubiquitin-based immunomodulator. Monomeric ubiquitin is the main component of Transferon Oral®.

Proposed mechanism of action

Intravenously administered ubiquitin reduces inflammation and increases the survival rate in preclinical models of sepsis. It acts extracellularly as a cytokine-like protein with anti-inflammatory properties, probably through interaction with the CXCR-4/CXCL12 axis or through cellular internalization by mechanisms still under investigation.

Objective of the project

Develop a small protein with modulatory effects on the immune system for oral administration, capable of controlling inflammation in diseases such as allergic rhinitis.

Reference

Majetschak M. Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J. Leukoc. Biol. 2011;  89(2). Doi: 10.1189/jlb.0510316

 

Vallejo-Castillo L, et al. Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract «Transferon Oral»: The Starting Point to Understand Its Mechanism of Action. Front Pharmacol. 2020; 11:569039. doi: 10.3389/fphar.2020.569039.